Clinical Trials Directory

Trials / Completed

CompletedNCT01788449

Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

Association of Antibiotic Measures and Control of Bacterial Resistance

Status
Completed
Phase
Study type
Observational
Enrollment
335 (actual)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.

Detailed description

Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.

Conditions

Timeline

Start date
2005-05-01
Primary completion
2007-02-01
Completion
2007-02-01
First posted
2013-02-11
Last updated
2013-02-13

Source: ClinicalTrials.gov record NCT01788449. Inclusion in this directory is not an endorsement.